LRFFT1 cell construction method

Abstract

The invention provides an LRFFT1 cell construction method, human peripheral blood is used to sequence ctDNA or a whole exome of a tumor tissue, a mutation site is screened to predicate an epitope, andthe sequence of an expression gene of a mutation polypeptide is connected and synthesized; meanwhile, a lentiviral vector is constructed, a lentivirus is packaged, an APC (Antigen Presenting Cell) istransfected to finish the transformation of a specific LV cell, the APC is cultured in vitro together with a PBMC (Peripheral Blood Mononuclear Cell) separated from the peripheral blood, the effective polypeptide is screened, a common T cell is transformed into an RFF cell having more accurate lethality through the second impact stimulated by the accurate effective polypeptide; the transformationis conducted through the TCR-T technical principle; an immunosuppressive target of the transformed T cell is then knocked off through the gene editing technology, the specific lethal T cell is protected accurately against in-vivo suppression, the lethality of the T cell on a tumor cell is improved, and a more offensive and defensive LRFFT1 cell is obtained.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a method for constructing LRFFT1 cells. Background technique [0002] At present, in terms of tumor-specific immunotherapy, the existing LAK, DC, CIK, and DC-CIK cells and methods have basically been proved to be ineffective, while NK, CAR-NK, TIL and other cell technologies have yet to mature. CAR- T cells also have shortcomings in safety and solid tumor therapy. In the prior art, DCs are generally modified to present T cells to produce specific killing. Some laboratories are trying to use viruses as vectors to transfect and present T cells to induce specific killing of T cells. We have also used mutant hybrid peptides to directly stimulate PBMCs to induce T cells. There are also laboratories using TCR-T technology to target the presentation of MAGE A3 antigen. [0003] The above treatment methods are immature, especially the in vitro induction of DC cells and the te...

AI Technical Summary

Problems solved by technology

There is a general lack of accurate and effective analysis of patient antigens

Images